Ask AI
ProCE Banner Activity

DeLLphi-304 Phase III Trial: Post Hoc Analysis of Intracranial Efficacy of Tarlatamab vs Chemotherapy as Second-line Treatment for SCLC

Conference Coverage
Slideset

Results from the phase III DeLLphi-304 trial supported the use of tarlatamab vs chemotherapy as second-line treatment for patients with SCLC. Post hoc analysis further confirms the intracranial efficacy of tarlatamab in the second-line setting for patients with SCLC, including those with brain metastases.

Released: June 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and PharmaMar.

Lilly

PharmaMar

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate pivotal ASCO 2026 lung cancer data and expert guidance to optimize biomarker-driven treatment selection, sequencing, and monitoring across disease stages

  • Apply prognostic and predictive biomarkers to accurately identify patients most likely to benefit from targeted, immunotherapy-based, and emerging treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for lung cancer to accelerate their effective incorporation into clinical practice